SCHEMBL5756098

SCHEMBL5756098

Cc1cc(Br)c2nc(Cl)nc(O)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 2/20 0.39
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
NQO2 P16083 1/20 0.37
LMNA P02545 2/20 0.34
HPGD P15428 1/20 0.34
NOD2 Q9HC29 1/20 0.34
MAPT P10636 2/20 0.33
DHODH Q02127 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30634862 0.82 PRNP (0.38) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL17884005 0.82 PRNP (0.38) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL5754888 0.82 PRNP (0.40) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL31284109 0.79 NQO2 (0.30) NQO2
SCHEMBL17873529 0.79 HTT (0.44) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL22258816 0.79 NQO2 (0.30) NQO2
SCHEMBL30783955 0.77 PRNP (0.35) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL31724977 0.76 PRNP (0.34) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL26671302 0.76 PRNP (0.34) PRNPHTTNPSR1PPARGNCOA2
SCHEMBL27291620 0.76 PRNP (0.39) PRNPHTTNPSR1PPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024026424-A1 QUINAZOLINONE DERIVATIVES AS AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
EP-1218358-B1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2006-09-13 EP disclosed
EP-1218358-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS AstraZeneca AB (SE) 2002-07-03 EP disclosed
US-6399603-B1 QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY ASTRAZENECA AB (SE) 2002-06-04 US disclosed
WO-2001021598-A1 THERAPEUTIC QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2001-03-29 WO disclosed